{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-005141","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.313263+00:00","generated_at":"2026-06-20T17:10:46.584763+00:00","sec_items":["2.02","7.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Amneal reaffirms FY2022 guidance: revenue $2.15-2.25B, adj. EBITDA $500-520M","bullets":["Reaffirmed FY2022 net revenue guidance of $2.15B-$2.25B; no change from Nov 4, 2022.","Adjusted EBITDA forecast unchanged at $500M-$520M; adjusted diluted EPS $0.65-$0.70.","Operating cash flow guidance $200M-$225M; capex $65M-$75M; diluted shares ~305M.","Guidance includes 100% of AvKARE EBITDA; accounts for 35% non-controlling interest.","Opana ER antitrust litigation cash payments of ~$131M excluded from operating cash flow guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-005141","json":"https://secwatch.observer/filing/0001193125-23-005141.json","markdown":"https://secwatch.observer/filing/0001193125-23-005141.md","text":"https://secwatch.observer/filing/0001193125-23-005141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523005141/0001193125-23-005141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523005141/d416892d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:10:46.584763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9dc15aec364d03bcaf15a389b26c55587b912d9","claim":"Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.15 billion - $2.25 billion, EPS $0.65 - $0.70. Guidance reaffirmed.","evidence_excerpt":"In connection with a presentation to be made at an investor conference on January 10, 2023, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), reaffirms previously issued guidance with respect to the year ended December 31, 2022, which was previously issued on November 4, 2022 in connection with the Company’s third quarter 2022 results: Full Year 2022 Financial Guidance Net revenue $2.15 billion - $2.25 billion Adjusted EBITDA (1) $500 million - $520 million Adjusted diluted EPS (2) $0.65 - $0.70 Operating cash flow (3) $200 million - $225 million Capital expenditures $65 million - $75 million Weighted average diluted shares outstanding (4) Approximately 305 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523005141/0001193125-23-005141-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$2.15 billion - $2.25 billion"},{"label":"EPS","value":"$0.65 - $0.70"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}